Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Dabigatran Shows Non-Inferiority to Warfarin: BI
December 21, 2009
- Wholesalers’Primary Profit on Sales -2.04% in FY2008: Mr Matsutani
December 21, 2009
- Sumitomo Chemical, Kracie to Codevelop Scabies Treatment
December 21, 2009
- Diversifying Business Not the Cure for “Patent Cliff”: Datamonitor
December 21, 2009
- BioComber Licenses Cell-Free Protein Synthesis Technology to Chugai
December 21, 2009
- Merck Serono Aims at 10% Market Share for hGH Saizen
December 21, 2009
- 60% of ED Treatments Sold Online Are Counterfeits
December 21, 2009
- TMX-67 to Drive Teijin's Business: Mr Ohyagi
December 21, 2009
- Benefits of an Attitude of Gratitude
December 21, 2009
- Takara Bio Obtains Patent on Expansion Culture of Lymphocytes
December 21, 2009
- DPP-4/GLP-1 Drugs Need Further Assessment in Actual Medical Practice: Prof. Niki
December 21, 2009
- CMIC Acquires DS Propharma's Shizuoka Plant
December 21, 2009
- Taxotere to Become New Treatment Option for Prostate Cancer: Prof. Akaza
December 21, 2009
- GSK Files for Rotavirus Vaccine Rotarix
December 14, 2009
- DSP to Spin Off Animal Health, Food & Speciality Products
December 14, 2009
- FDA Advisory Committee Supports Safety, Efficacy of Prevnar 13
December 14, 2009
- EFPIA Japan Appoints Masuhiro Kato Chairman
December 14, 2009
- More Than 60% of Patients Dissatisfied with Existing Oral Hypoglycemic Agents
December 14, 2009
- No New Safety Measures Required for Lantus: PMDA
December 14, 2009
- GRU's WG Demands Reductions in METI's Budgets for Drug Discovery Research
December 14, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…